ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the completion of the sale, the senior vice president now owns 233,226 shares of the company's stock, valued at $15,537,516.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Chad Gassert also recently made the following trade(s):
- On Monday, April 1st, Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00.
ANI Pharmaceuticals Stock Up 0.2 %
Shares of NASDAQ ANIP opened at $67.25 on Friday. The stock has a fifty day moving average price of $66.58 and a 200 day moving average price of $59.16. The company has a market cap of $1.42 billion, a P/E ratio of 80.06 and a beta of 0.80. ANI Pharmaceuticals, Inc. has a 12-month low of $37.64 and a 12-month high of $70.81. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.
Hedge Funds Weigh In On ANI Pharmaceuticals
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 248 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $34,000. Pacer Advisors Inc. purchased a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $41,000. AJOVista LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $58,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $132,000. 76.05% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Truist Financial upped their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, March 1st. Guggenheim reissued a "buy" rating and set a $77.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. HC Wainwright upped their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a "buy" rating in a research note on Monday, March 4th. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an "overweight" rating and a $80.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $80.00.
Read Our Latest Analysis on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
